Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
2.
J Travel Med ; 26(8)2019 Dec 23.
Article in English | MEDLINE | ID: mdl-31355414

ABSTRACT

BACKGROUND: We conducted a comprehensive investigation to update our knowledge of traveler's diarrhea (TD) etiology and antimicrobial resistance (AMR) in Nepal. METHODS: A case-control study of TD etiology was conducted at the CIWEC Clinic Travel Medicine Center in Kathmandu from 2012 to 2014. Stool samples were tested by microscopy, culture and molecular techniques for identification of bacterial, viral and parasitic enteric pathogens, and AMR. We analysed patient demographic data, pre-treatment information and clinical outcomes. RESULTS: We enrolled 433 TD cases and 209 non-diarrhea controls. At least one of enteric pathogens was identified among 82% of cases and 44% of controls (P < 0.001). Multiple pathogens were observed among 35% of cases and 10% of controls. The most common pathogens significantly identified among cases in comparison with controls were Campylobacter (20%), norovirus (17%), enterotoxigenic E. coli (ETEC) (12%), rotavirus (9%) and Shigella (8%) (P < 0.001). We noted Campylobacter, Shigella and ETEC resistance to azithromycin at 8, 39 and 22% and to ciprofloxacin at 97, 78 and 23%, respectively. CONCLUSION: Among travellers to Nepal with TD, viral pathogens were commonly found and norovirus was the second most common pathogen after campylobacter. We noted increased AMR to fluoroquinolones (FQs) and azithromycin (AZM). There is heightened concern for AZM treatment failures, though this continues to remain the drug of choice for TD treatment in our setting where FQs should not be used.


Subject(s)
Diarrhea/diagnosis , Drug Resistance, Microbial , Travel Medicine/methods , Travel , Adolescent , Adult , Anti-Infective Agents/therapeutic use , Azithromycin/therapeutic use , Campylobacter/isolation & purification , Case-Control Studies , Diarrhea/drug therapy , Diarrhea/microbiology , Escherichia coli/isolation & purification , Female , Fluoroquinolones/therapeutic use , Humans , Logistic Models , Male , Middle Aged , Nepal , Norovirus/isolation & purification , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL